NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $47.00.

Several research analysts have issued reports on NAMS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Royal Bank Of Canada upped their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Needham & Company LLC lifted their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Leerink Partners restated an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Finally, HC Wainwright started coverage on shares of NewAmsterdam Pharma in a research report on Monday, October 20th. They set a “buy” rating and a $52.00 price target for the company.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00. Following the completion of the sale, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 32,612 shares of the stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $774,425.40. The trade was a 57.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 298,647 shares of company stock valued at $10,236,050 in the last quarter. Corporate insiders own 20.84% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Jennison Associates LLC increased its stake in NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Knights of Columbus Asset Advisors LLC acquired a new position in shares of NewAmsterdam Pharma in the 2nd quarter valued at $595,000. Franklin Resources Inc. increased its position in shares of NewAmsterdam Pharma by 30.6% in the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after buying an additional 78,300 shares in the last quarter. Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after buying an additional 490,656 shares during the period. Finally, Maverick Capital Ltd. lifted its holdings in NewAmsterdam Pharma by 178.8% during the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after acquiring an additional 982,405 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Down 1.4%

Shares of NASDAQ:NAMS opened at $31.44 on Friday. The firm has a market cap of $3.56 billion, a P/E ratio of -15.34 and a beta of 0.07. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $42.00. The company’s 50-day moving average price is $35.20 and its two-hundred day moving average price is $31.25.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. As a group, equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.